SMC Scottish Medicines Consortium
Advising on new medicines for Scotland
www.scottishmedicines.org.uk
NHS SCOTLAND
Delta House • 50 West Nile Street • Glasgow • G1 2NP • Tel 0141 225 6999 • Chairman: Dr Alan G MacDonald

Product Update

sevelamer carbonate 2.4g powder for oral suspension (Renvela®)

SMC No 1304/18

Sanofi

12 January 2018

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

sevelamer carbonate (Renvela®) is accepted for restricted use within NHS Scotland.

Indication under review: control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m^2) with chronic kidney disease.

SMC restriction: the second-line management of hyperphosphataemia in patients receiving haemodialysis.

SMC has previously accepted sevelamer carbonate for restricted use in the second-line management of hyperphosphataemia in adult patients receiving haemodialysis.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 13 November 2017.

Chairman
Scottish Medicines Consortium

Published 12 February 2018